-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $117

Benzinga·12/22/2025 18:18:43
語音播報
B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $80 to $117.